Corona virus vaccine trials are ongoing worldwide. The most expected of all the vaccines is being done with the Oxford vaccine. Trials of Oxford University are going on in many countries of the world. The clinical trial of this vaccine is to be done in India, but the trial of this vaccine to be held at The Post Graduate Institute of Medical Education and Research (PGIMER) in Chandigarh has been postponed for a week. The trial was to begin in the first week of September.
Some reasons for security are being cited behind this week’s delay. The Data Safety Monitoring Board (DSMB) informed the news agency IANS that due to lack of safety approval, the trial has been postponed for a week. 100 people have been selected for this trial.
Due to delay in trial, recruitment of more volunteers has been stopped. Currently 400 people have registered for the trial, in which 253 people will be given the first dose of the vaccine. Professor Madhu Gupta, Principal Investigator of Vaccine Trial Schedule at PGIMER, said, “At the moment, recruitment of volunteers for the trial of Oxford Vaccine has been put on hold as we have been approved by the Data Safety Monitoring Board for the safety of the first 100 Volunteers. Are waiting.
Professor Madhu Gupta said, ‘Now any update in this matter will be given only till next week.’ Professor Gupta had earlier reported that a total of 16 staff along with him would oversee this clinical trial.
Let us tell you that PGIMER is one of the 17 places that have been selected for the Human Clinical Trial. The vaccine is being produced in collaboration with Oxford University AstraZeneca. After the trial is complete, the production and marketing of this vaccine will be done by the Serum Institute of India (SII), Pune.
The Serum Institute of India is one of the largest vaccine producers in the country. A few days ago, the Serum Institute said that by the end of this year, the corona virus vaccine will be made. Meanwhile, Russia has also said that it will make its vaccine Sputnik V available to common citizens this week.